The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Various cyclin-dependent kinase (Cdk) complexes have been implicated in the regulation of transcription. In this study, we identified a 70-kDa Cyclin K (CycK) that binds Cdk12 and Cdk13 to form two different complexes (CycK/Cdk12 or CycK/Cdk13) in human cells. The CycK/Cdk12 complex regulates phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and expression of a small subset of human genes, as revealed in expression microarrays. Depletion of CycK/Cdk12 results in decreased expression of predominantly long genes with high numbers of exons. The most prominent group of down-regulated genes are the DNA damage response genes, including the critical regulators of genomic stability: BRCA1 (breast and ovarian cancer type 1 susceptibility protein 1), ATR (ataxia telangiectasia and Rad3-related), FANCI, and FANCD2. We show that CycK/Cdk12, rather than CycK/Cdk13, is necessary for their expression. Nuclear run-on assays and chromatin immunoprecipitations with RNA polymerase II on the BRCA1 and FANCI genes suggest a transcriptional defect in the absence of CycK/Cdk12. Consistent with these findings, cells without CycK/Cdk12 induce spontaneous DNA damage and are sensitive to a variety of DNA damage agents. We conclude that through regulation of expression of DNA damage response genes, CycK/Cdk12 protects cells from genomic instability. The essential role of CycK for organisms in vivo is further supported by the result that genetic inactivation of CycK in mice causes early embryonic lethality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Micro3 showed similarities to HM_3, HM_4 phenotype but also expressed APOE, apoptosis associated genes XAF1, YWHAB, YWHAG, YWHAE encoding 14–3-3 protein subunits, cell-cycle and cell division control genes CDK12, MIS18BP1, TAF1D, BOD1L1 and CCAR1 [6, 30, 67].”
From Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics (2024) · cites this paper as [6]
In the citing paper
“To execute their functions, CDK12 and CDK13 form two separate complexes with CCNK (Blazek et al., 2011; Cheng et al., 2012).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 inactivation is known to cause reduced POLII elongation and premature polyadenylation of select genes enriched in the DNA damage response pathway, resulting in a BRCAness phenotype (Blazek et al., 2011; Dubbury et al., 2018; Johnson et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 forms a complex with CCNK to act as a transcriptional regulator of genes critically involved in DDR pathways (Blazek et al., 2011;Krajewska et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Blazek et al., 2011
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 4×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundInfluentialThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075 · cited 2×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundThe DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623 · cited 2×
“DNA double-stranded breaks (DSBs) and DNA interstrand cross-links (ICLs) are among the most severe DNA lesions (Harper and Elledge 2007; Bonner et al. 2008; Jackson and Bartek 2009; Moldovan and D’Andrea 2009).”
Backgroundc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279 · cited 1×
“P-TEFb is considered to be the major Ser2 kinase and was implicated in the regulation of transcriptional elongation of most, if not all, protein-coding genes (Chao et al. 2000; Nechaev and Adelman 2008; Rahl et al. 2010).”
BackgroundControlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144 · cited 3×
“Phosphorylation of serine at position 2 (Ser2) is thought to be responsible for productive transcriptional elongation and synthesis of full-length mature mRNA (Peterlin and Price 2006; Bres et al. 2008).”
BackgroundSelf-citationRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138 · cited 13×
“To determine how depletion of P-TEFb and the CycK/Cdk12 complex affects BRCA1 protein levels and global phosphorylation of Ser2, we knocked down both cyclin subunits of P-TEFb and the CycK/Cdk12 complex (Fig.”
BackgroundInfluentialiCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution
König, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D. J., Luscombe, N. M., & Ule, J. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1838 · Cited by 1,126 · cited 1×
“CEL files were first analyzed with version 3 of ASPIRE software (Konig et al. 2010).”
MethodSelf-citation
Research works printed but not linked: 1
- 10.1038/nature10166 · DOI · Paper page
Cited by
Items 301–400 of 542
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
Collet, L., Péron, J., Penault-Llorca, F. M., Pujol, P., Lopez, J., Freyer, G., & You, B. (2022) · Cancers · doi:10.3390/cancers14030599 · Cited by 13
“In addition, rearrangements of other genes that are not directly involved in DNA repair could also confer PARPi sensitivity, such as CDK12 deficiency [54,55], or the recently described EWS-FLI1 fusion [56].”
BackgroundDisrupting the Molecular Pathway in Myotonic Dystrophy
Xing, X., Kumari, A., Brown, J., & Brook, J. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413225 · Cited by 12
“CDK12 and CDK13 are metazoan orthologs of the Saccharomyces cerevisiae gene Ctk1 [8,9].”
BackgroundCDK regulation of transcription by RNAP II: Not over ‘til it's over?
Fisher, R. P. (2016) · Transcription · doi:10.1080/21541264.2016.1268244 · Cited by 18
Wang, Z., Himanen, S. V., Haikala, H. M., Friedel, C. C., Vihervaara, A., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad792 · Cited by 15
“First, both concentrations of THZ531 but not 400 nM of THZ532 led to a time-and dose-dependent decrease in mRNA levels of BRCA1 and FANCD2 , the established CDK12-dependent genes of the HR pathway ( 9 ,31 ) (Supplementary Figure S1A).”
BackgroundResultInfluentialInterplay between altered metabolism and DNA damage and repair in ovarian cancer
Uboveja, A., & Aird, K. M. (2024) · BioEssays · doi:10.1002/bies.202300166 · Cited by 14
“[149,150] This makes up ~12% of all HGSOCs.”
Role of specific CDKs in regulating DNA damage repair responses and replication stress
Roy, R., Gampa, S. C., & Garimella, S. V. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2024.102485 · Cited by 13
Troester, S., Eder, T., Wukowits, N., Piontek, M., Fernández‐Pernas, P., Schmoellerl, J., Haladik, B., Manhart, G., Allram, M., Maurer‐Granofszky, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59930-9 · Cited by 14
“Our data show that CDK12 is crucial for the growth of NUP98::KDM5A -driven leukemia in vitro and in vivo and that small-molecule-mediated perturbation of CDK12 leads to a profound downregulation of genes involved in DNA repair, as reported in previous studies 47,48,53,74 .”
Tien, J. C.-Y., Zhai, Y., WU, R. T., Zhang, Y., Chang, Y., Cheng, Y., Todd, A. J., Wheeler, C. E., Li, S., Mannan, R., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426909122 · Cited by 13
“Previous speculation on CDK12 tumor suppressor function focused on its role in maintaining genomic integrity ( 15 ).”
Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer
Arce‐Gallego, S., Athie, A., Pritchard, C. C., & Mateo, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_12 · Cited by 11
A patent and literature review of CDK12 inhibitors
Tang, R., Liu, J., Li, S., Zhang, J., Yu, C., Liu, H., Chen, F., Lv, L., Zhang, Q., Yuan, K., et al. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2126765 · Cited by 12
Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns
Sørensen, S. G., Shrikhande, A., Poulsgaard, G. A., Christensen, M. H., Bertl, J., Laursen, B. E., Hoffmann, E. R., & Pedersen, J. S. (2023) · eLife · doi:10.7554/elife.81224 · Cited by 12
“High predictive power for CDK12 deficiency CDK12 encodes a kinase that regulates transcriptional and post-transcriptional processes of the DDR ( Blazek et al., 2011 ; Marqués et al., 2000 ; Li et al., 2016 ).”
Stagni, V., Orecchia, S., Mignini, L., Beji, S., Antonioni, A., Caggiano, C., Barilà, D., Bielli, P., & Sette, C. (2022) · Cancers · doi:10.3390/cancers14163847 · Cited by 13
“CDK12, a cyclin-dependent kinase that phosphorylates the RNA polymerase II [21], ensures proper expression of DDR genes by suppressing intronic alternative polyadenylation and premature transcript termination [22,23], whereas the inositol polyphosphate multikinase (IPMK) guarantees nuclear export of transcripts involv…”
BackgroundO'Malley, D. E., Raspin, K., Melton, P. E., Burdon, K. P., Dickinson, J. L., & FitzGerald, L. M. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02485-7 · Cited by 11
“Tandem duplication through somatic CDK12 loss of function CDK12 , located at 17q12 and encoding cyclin-dependent kinase 12 , regulates the expression of genes involved in the cell cycle and homologous repair DDR pathway, and is required for the maintenance of genomic stability [12].”
Pitolli, C., Marini, A., Sette, C., & Pagliarini, V. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01413-3 · Cited by 12
“Earlier studies showed that while depletion of CDK12 strongly reduced RNAPII S2 phosphorylation, knockdown of CDK13 caused only partial or no effects [36, 37].”
Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 12
“Moreover, CDK12 knockdown results in cellular accumulation at the G2/M phase, which may be due to the activation of the DNA damage cell cycle checkpoint following a reduction in CDK12-dependent DNA repair gene expression [32,64].”
Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12/13
Xia, M., Li, Z., Jiang, H., Li, Y., Hu, L., He, Y., Huang, S., Tang, L., Luo, C., Gu, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117378 · Cited by 10
Sun, R., Peng, J. C., Wang, Z., Yan, B., Zhu, S., Huang, Z., Zhang, J., Ding, D., Li, X., Wang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413732122 · Cited by 11
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Nouruzi, S., Kobelev, M., Tabrizian, N., Gleave, M. E., & Zoubeidi, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00282-8 · Cited by 15
“A phenotype where tumors exhibit defects in HRR despite not having BRCA1/2 mutations, potentially making them sensitive to PARP inhibitors.”
InfluentialP-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway
Wang, Z., Mačáková, M., Bugai, A., Kuznetsov, S. G., Hassinen, A., Lenasi, T., Potdar, S., Friedel, C. C., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad001 · Cited by 11
“Upon the release of Pol II from pausing, the homologous CDK12 and CDK13 interact with cyclin K to stimulate Pol II elongation throughout gene bodies and facilitate production of full-length transcripts through suppressing their premature cleavage and polyadenylation (12,13).”
Direct and indirect effects of CYTOR lncRNA regulate HIV gene expression
Kuzmina, A., Sadhu, L., Hasanuzzaman, M., Fujinaga, K., Schwartz, J. C., Fackler, O., & Taube, R. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012172 · Cited by 9
CDK7–CDK11 axis in spliceosome regulation and pre-mRNA splicing
Rájecký, M., Gajdušková, P., Maník, P., Hluchý, M., Hegedűsová, E., Kryštofová, K., Potěšil, D., Martínková, P., Slabá, Z., Khirsariya, P., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1343 · Cited by 10
“S5 C) and the absence of a global splicing defects after CDK12 inhibition [ 72 , 78 , 80–82 , 86– 88 ].”
Decaesteker, B., Durinck, K., Roy, N. V., Wilde, B. D., Neste, C. V., Haver, S. V., Roberts, S. S., Preter, K. D., Vermeirssen, V., & Speleman, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121286 · Cited by 10
Chilà, R., Chiappa, M., Guffanti, F., Panini, N., Conconi, D., Rinaldi, A., Cascione, L., Bertoni, F., Fratelli, M., & Damia, G. L. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903536 · Cited by 10
“However, a wide gene expression analysis indicated a certain proportion of deregulated genes (both up- and down-regulated), but we did not find any clear enrichment in DNA repair genes among the downregulated transcripts as reported elsewhere (4, 40).”
BackgroundResultInfluentialPrognostic Value of Genomic Mutations in Metastatic Prostate Cancer
Zhu, H., Ding, Y., Huang, H., Lin, Q., Chen, W., & Yu, Z. (2022) · Heliyon · doi:10.1016/j.heliyon.2023.e13827 · Cited by 12
DNA damage signals from somatic uterine tissue arrest oogenesis through activated DAF-16
Sarkar, G. C., Rautela, U., Goyala, A., Datta, S., Anand, N., Singh, A., Singh, P., Chamoli, M., & Mukhopadhyay, A. (2023) · Development · doi:10.1242/dev.201472 · Cited by 8
Kuchukulla, R. R., Hwang, I., Kim, S. H., Kye, Y.-H., Park, N., Cha, H., Moon, S., Chung, H. W., Lee, C., Kong, G., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116014 · Cited by 9
Functional Interplay between PPM1G and the Transcription Elongation Machinery
Gudipaty, S. A., & D’Orso, I. (2016) · RNA & DISEASE · doi:10.14800/rd.1215 · Cited by 14
Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions
Klein, M. A. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.11.009 · Cited by 9
Analysis of CDK12 alterations in a pan‐cancer database
Pan, E., Cabal, A., Javier-DesLoges, J. F., Patel, D. N., Panian, J. A., Lee, S., Shaya, J. A., Nonato, T. K., Xu, X., Stewart, T. F., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4483 · Cited by 10
Lin, S., Jiang, Q., Huang, X., Xu, J., Wu, L., & Liu, Y. (2023) · ACS Omega · doi:10.1021/acsomega.3c02912 · Cited by 9
Blažek, D., Teque, F., Mackewicz, C. E., Peterlin, B. M., & Levy, J. A. (2015) · Journal of General Virology · doi:10.1099/jgv.0.000326 · Cited by 10
“Approximately 2|10(6) of the infected CD4+ cells were used for the ChIP procedure that was performed as described (Blazek et al., 2011; Taube et al., 2002).”
MethodSelf-citationCassart, C., Yague‐Sanz, C., Bauer, F., Ponsard, P., Stubbe, F., Migeot, V., Wéry, M., Morillon, A., Palladino, F., Robert, V. J. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1450 · Cited by 9
CDK9 and H2B Monoubiquitination: A Well-Choreographed Dance
Johnsen, S. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002860 · Cited by 9
“Furthermore, two additional closely related CDK9 orthologs, CDK12/CRKRS and CDK13/CDC2L5, have been identified and implicated in metazoan transcriptional elongation [26,27].”
BackgroundWolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13
Acharya, A., Raza, S. I., Anwar, M. Z., Bharadwaj, T., Liaqat, K., Khokhar, M. A. S., Everard, J., Nasır, A., Nickerson, D. A., Bamshad, M. J., et al. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00922-0 · Cited by 8
“CDK13, expressed ubiquitously in human tissues, is part of the cyclin-dependent kinase family that regulates gene transcription, alternative splicing of RNA, and C-terminal domain (CTD) phosphorylation, along with CDK12 and cyclin K [14, 15].”
BackgroundGuo, X., Chen, H., Zhou, Y., Shen, L., Wu, S., & Chen, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2097067 · Cited by 7
“Furthermore, loss-of-function depletion of CDK12 can alter the expression of DDR-related genes (e.g. BRCA1, ATR, FANCI, and FANCD2) [44,48,54], oxidative stress response-related genes and stress-activated Nrf2 transcription factor [55], and thus cause impairment of cellular responses to DNA damage, stress, and heat sh…”
Roles of CDK12 mutations in PCa development and treatment
Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 10
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Stern, Y. E., Ghosh, P., Peroza, J., Solanki, H. S., Imbody, D. J., Bridenstine, L., Pandurangan, T., Frydman, S. M., Nickens, K. N., Walker-Mimms, H. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0450 · Cited by 7
Gurioli, G., Tedaldi, G., Farolfi, A., Petracci, E., Casanova, C., Comerci, G., Danesi, R., Arcangeli, V., Ravegnani, M., Calistri, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415789 · Cited by 9
“We also hypothesized a better clinical outcome in patients with the DNA damage response genes altered because of a worse platinum-induced DNA interstrand crosslinks repair capability [37].”
ResultZheng, M., Zhang, X., Chen, W., Xia, F., Yang, H., Yuan, K., & Yang, P. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0259 · Cited by 7
Horvath, R. M., Brumme, Z. L., & Sadowski, I. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01072-23 · Cited by 11
“Tat triggers efficient recruitment of P-TEFb, 94 consisting of CDK9 and Cyclin T1 (23) (24), which phosphorylates Serine 2 of RNAPII in 95 addition to the pausing factors DRB sensitivity-inducing factor (DSIF) and negative elongation 96 factor (NELF) resulting in enhanced transcriptional elongation (25) (26) (27) (28).”
BackgroundCyclin-dependent kinase 4 and 6 in cancer: Exploration of CDK4/6 inhibitors as anticancer agents
Nandi, N. K., Chahat, Bhatia, R., Chauhan, G., Kalra, S., & Kumar, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00006-1 · Cited by 9
Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types
Elliott, A., Zhang, J., Zhang, Q. H., Swensen, J. J., Martin, D., Xiu, J., Geynisman, D. M., Vaena, D. A., Herzog, T. J., Holloway, R. W., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.08.010 · Cited by 9
Comprehensive proteomic analysis reveals dynamic phospho‐profiling in human early erythropoiesis
Peng, Y., Tang, L., Li, Y., Song, J., Liu, H., Wang, P., Zhong, Z., Yang, Y., Wang, S., Chen, L., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18407 · Cited by 8
Zhang, G., Lan, B., Zhang, X., Lin, M., Liu, Y., Chen, J. S., & Guo, F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006483 · Cited by 7
“21 25 26 Until recently, it was confirmed that CDK12 suppresses intronic polyadenylation (IPA) of transcripts containing multiple intronic PA-sites, especially DDRs, enabling the production of functional full-length proteins.”
SIRT2 Directs the Replication Stress Response Through CDK9 Deacetylation
Zhang, H., Park, S., Pantazides, B. G., Hardy, C. W., Seyfried, N. T., Duong, D. M., & Yu, D. S. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.07.1808 · Cited by 7
Sensitizing HR-proficient cancers to PARP inhibitors
Lim, E., Johnson, S. F., Geyer, M., Serra, V., & Shapiro, G. I. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1299272 · Cited by 8
“Additionally, we have recently demonstrated that dinaciclib is the most potent inhibitor of CDK12 known thus far, and therefore a transcriptional regulator of HR genes.(7-10)”
BackgroundOttaviani, D., Ola, M., Allotta, A., Chaibi, Y. M., Hickey, S., Jagušt, P., Cosgrove, N. S., Cocchiglia, S., Bane, F. T., Fallon, R., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf295 · Cited by 6
“DNA replication and DDR genes, 12-15 but also to indirect mechanisms through its involvement in regulating other oncogenic pathways.”
BOD1L mediates chromatin binding and non-canonical function of H3K4 methyltransferase SETD1A
Hoshii, T., Kikuchi, S., Kujirai, T., Masuda, T., Ito, T., Yasuda, S., Matsumoto, M., Rahmutulla, B., Fukuyo, M., Murata, T., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae605 · Cited by 8
“SETD1A and cyclin K commonly regulate DNA damage repair pathways ( 2 ,4 ).”
BackgroundEarly embryogenesis in CHDFIDD mouse model reveals facial clefts and altered cranial neurogenesis
Hampl, M., Jandová, N., Lusková, D., Nováková, M., Szotkowská, T., Čada, Š., Procházka, J., Kohoutek, J., & Buchtová, M. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050261 · Cited by 6
Self-citationLautert-Dutra, W., Melo, C. M., Chaves, L. P., Crozier, C., Saggioro, F. P., dos Reis, R. B., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Molecular Cytogenetics · doi:10.1186/s13039-024-00680-6 · Cited by 7
“This interference affects the transcription elongation, splicing, cleavage, and polyadenylation of a group of genes, including those crucial for DDR [6, 7].”
BackgroundPearson, A. D. J., Chi, S. N., Laetscht, T. W., Marshall, L. V., Raetz, E. A., George, R. E., Chesler, L., Karres, D., Scobie, N., Knoderer, H. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115629 · Cited by 6
Guo, S., Liu, J., Zheng, H., & Wu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14040835 · Cited by 7
Li, Z., Li, X., Seebacher, N. A., Liu, X., Wu, W., Yu, S., Hornicek, F. J., Huang, C., & Duan, Z. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae051 · Cited by 5
Recent advances in congenital heart disease genomics
Wilsdon, A., Sifrim, A., Hitz, M., Hurles, M. E., & Brook, J. D. (2017) · F1000Research · doi:10.12688/f1000research.10113.1 · Cited by 6
Molecular complexity of intraductal carcinoma of the prostate
Zhu, S., Xu, N., & Zeng, H. (2024) · Cancer Medicine · doi:10.1002/cam4.6939 · Cited by 6
“12 73–75 Despite its importance, CDK12 is often excluded from DDR genetic testing panels in many studies regarding IDC-P.”
BackgroundZhang, H., Xing, C., Yan, B., Lei, H., Guan, Y., Zhang, S., Kang, Y., & Pang, J. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00260 · Cited by 6
Liu, Q., Dai, G.-R., Wang, X.-N., Wang, L., Li, L., Wu, Z., & Xia, R.-X. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00415-4 · Cited by 5
Wang, B., Wang, Y., Wen, Y., Zhang, Y., Ni, W., Tang, T., Cao, J.-Y., Yin, Q., Jiang, W., Yin, D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.012 · Cited by 6
“Since the development of CDK12 inhibitors, they have been increasingly used in the treatment of cancers.(5,45) However, renal function decline as well as water electrolyte disorders, including hyponatremia, hypochloridemia, hypokalemia, and hypotension (Table S1), have been repeatedly reported in clinical trials of CD…”
BackgroundMethodInfluentialRautela, U., Sarkar, G. C., Chaudhary, A., Chatterjee, D., Rosh, M., Arimbasseri, G. A., & Mukhopadhyay, A. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011453 · Cited by 4
“Interestingly, in that study, the function of the CDK-12 was found to be independent of its canonical cyclin, cyclin K/CCNK-1 [53].”
Cao, Y., Huang, S., He, Y., Zhang, Y., Chen, S., Huang, M., He, F., Chen, S., Wang, L., Yang, Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108302 · Cited by 4
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness
Costanzo, F. D., Williamson, J., Robson, C. N., Gaughan, L., Conteduca, V., Mansour, W. Y., Formisano, L., Demichelis, F., Oing, C., & Rescigno, P. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0724 · Cited by 4
Multiple roles of CTDK-I throughout the cell
Srivastava, R., Duan, R., & Ahn, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03118-0 · Cited by 4
The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
Borowczak, J., Szczerbowski, K., Maniewski, M., Zdrenka, M., Słupski, P., Andrusewicz, H., Łysik-Miśkurka, J., Rutkiewicz, P., Bodnar, M., & Szylberg, Ł. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02994-6 · Cited by 5
“In settings of cellular stress, p53 recruits various mediators, such as cyclin K, which control the transcription of DNA damage response genes and protect cells from genomic instability [51, 52].”
BackgroundZhang, Y., Tang, T., Ni, W., Li, Z.-T., Jiang, L.-Y.-Z., Wang, Y., Zhou, X., Cao, J.-Y., Yin, Q., Jiang, W., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90872 · Cited by 5
Long, X., Steurer, B., Wong, C. W., Kozlova, E., Naumov, V., Pun, F. W., Aliper, A., Ren, F., & Zhavoronkov, A. A. (2024) · Future Medicine AI · doi:10.2217/fmai-2023-0019 · Cited by 5
Telomemore enables single-cell analysis of cell cycle and chromatin condensation
Yakovenko, I., Mihai, I. S., Selinger, M., Rosenbaum, W., Dernstedt, A., Gröning, R., Trygg, J., Carroll, L. M., Forsell, M. N. E., & Henriksson, J. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf031 · Cited by 4
“It is therefore possible that CDK13 upregulates DNA damage response genes, as previously shown for CDK12 [ 95 ], and thereby helps control the dose of SHM.”
Bristy, N. A., Fu, X., & Schwartz, R. S. (2025) · Journal of Computational Biology · doi:10.1089/cmb.2024.0613 · Cited by 7
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Rahman, R., & Selth, L. A. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102378 · Cited by 5
“Accordingly, CDK12 mutations are associated with genomic instability in many cancer types, including prostate cancer [58,81,95].”
Alteration of SC35 localization by transfection reagents
Damodaran, A. P., Courthéoux, T., Watrin, E., & Prigent, C. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118650 · Cited by 4
“Loss of RNA polymerase II Ser2 and Ser5 phosphorylation is known to affect the expression of genes such as XIAP, BRCA1 and FANCD2 [19,20].”
BackgroundDai, W., Wang, H., Zhan, Y., Li, N., Li, F. R., Wang, J., Yan, H., Zhang, Y., Wang, J., Wu, L., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26766 · Cited by 6
“In addition, early embryonic lethality of Ccnk straight knockout (KO) ( Ccnk (cid:1) / (cid:1) ) mice 6 precluded the possibility that we may use this in vivo model to investigate mechanisms by which CycK regulates brain development.”
BackgroundInfluentialBlažek, D. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2184 · Cited by 4
Holmes, F. A., Levin, M. K., Cao, Y., Balasubramanian, S., Ross, J. S., Krekow, L., McIntyre, K. J., Osborne, C. R. C., Espina, V. A., Liotta, L. A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00292 · Cited by 5
Messina, G., Prozzillo, Y., Bizzochi, G., Marsano, R. M., & Dimitri, P. (2022) · Cells · doi:10.3390/cells11193058 · Cited by 5
Johnson, E. M., Jayabalan, R., Patra, S. K., & Suh, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.05.539559 · Cited by 4
Frank, S. B., Persse, T. W., Coleman, I., Bankhead, A., Li, D., Sarkar, N. D., Wilson, D., Rudoy, D., Vashisth, M., Galipeau, P., et al. (2025) · eLife · doi:10.7554/elife.100081 · Cited by 4
Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K
Hayashi, K., Hoshii, T., Ning, M., Matsumoto, M., Izumi, S., Fukuyo, M., Rahmutulla, B., Tanabe, M., & Kaneda, A. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02101-x · Cited by 5
“Cyclin K is a critical cofactor of CDK12/13, which promote transcription through RNAPII phosphorylation [45, 46].”
Function of CDK12 in Tumor Initiation and Progression and Its Clinical Consequences
Vrábel, D., Svoboda, M., Navrátil, J., & Kohoutek, J. (2014) · Klinicka onkologie · doi:10.14735/amko2014340 · Cited by 3
“A právě CDK12 specificky fosforyluje v CTD doméně RNAPII serin v pozici 2 (Y1S2P3T4S5P6S7) a tím umožňuje přechod transkripce z iniciační do elongační fáze [11,19].”
InfluentialSelf-citationThe role of CDK12 in tumor biology
Dzimková, M., Procházková, J., Klát, J., & Kohoutek, J. (2020) · Klinicka onkologie · doi:10.14735/amko2020260 · Cited by 3
“etoposid, mitomycin C a kamptotecin [19].”
InfluentialSelf-citationBae, W. H., Hwang, J. Y., Hur, W. K., Choi, J., Nam, M., Choi, Y., Kim, L., Kim, E., Fridland, S., Cho, H. S., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00400 · Cited by 3
Biomarker-Driven Immunotherapy for Precision Medicine in Prostate Cancer
Ottini, A., Sepe, P., Beninato, T., Claps, M., Guadalupi, V., Verzoni, E., Giannatempo, P., Baciarello, G., de Braud, F., & Procopio, G. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0079 · Cited by 6
CDK12 Is Necessary to Promote Epidermal Differentiation Through Transcription Elongation
Li, J., Tiwari, M., Chen, Y., Luanpitpong, S., & Sen, G. L. (2022) · Stem Cells · doi:10.1093/stmcls/sxac002 · Cited by 5
Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers
Mir, M. A., & Jan, U. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_10 · Cited by 4
Mutational landscape of head and neck cancer and cervical cancer in Chinese and Western population
Li, Q., Zhu, G., Zhang, L., Zeng, B., Cai, T., Wu, J., Wei, B., Xie, Z., He, L., Tang, W., et al. (2023) · Head & Neck · doi:10.1002/hed.27603 · Cited by 3
CDK12 antagonizes a viral suppressor of RNAi to modulate antiviral RNAi in Drosophila
Zhang, L., Liang, Y., Qin, J., Liu, C., Shang, M., & Sun, X. (2024) · mBio · doi:10.1128/mbio.02868-24 · Cited by 3
Olaparib for the Treatment of Metastatic Prostate Cancer
Maurice‐Dror, C., Wyatt, A. W., & Chi, K. N. (2021) · Future Oncology · doi:10.2217/fon-2020-1245 · Cited by 5
Serbezov, D., Balabanski, L., Karachanak-Yankova, S., Vazharova, R., Nesheva, D. V., Hammoudeh, Z., Staneva, R., Mihaylova, M., Damyanova, V., Antonova, O., et al. (2019) · Journal of Aging Science · Cited by 3
Qureshi, M. F. H., Shah, M., Lakhani, M., Abubaker, Z. J., Mohammad, D., Farhan, H., Zia, I., Tafveez, R., Khan, S. T., Ghani, R., et al. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.209 · Cited by 3
“While CDK12 is known to protect the normal cell from DNA damage and is involved in the regulation of RNA polymerase II (RNApol II) [30-31].”
BackgroundDifferent Cyclins and Their Significance in Breast Cancer
Mir, M. A., & Qayoom, H. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_17 · Cited by 3
CHIEN, J. R., & Mehta, G. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001117 · Cited by 3
A role for CDK9 in UV damage response
Morawska, M. (2012) · Cell Cycle · doi:10.4161/cc.20963 · Cited by 3
CDK13 Mutations Drive Melanoma via Accumulation of Prematurely Terminated TranscriptsPreprint
Insco, M. L., Abraham, B. J., Dubbury, S. J., Dust, S., Wu, C., Chen, K. Y., Liu, D., Ludwig, C. G., Bellaousov, S., Fabo, T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/824193 · Cited by 3
“391 In vitro Kinase Assays: 392 Radioactive kinase reactions were performed using recombinant human CDK13 (694-1039) and 393 Cyclin K (1-300) proteins.”
MethodMcGregor, B. A., & Wei, X. X. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00080 · Cited by 3
Large tandem duplications in cancer result from transcription and DNA replication collisionsPreprint
Yang, Y., Badura, M. L., O’Leary, P. C., Delavan, H. M., Robinson, T. M., Egusa, E. A., Zhong, X., Swinderman, J. T., Li, H., Zhang, M., et al. (2023) · medRxiv · doi:10.1101/2023.05.17.23290140 · Cited by 3
“In the context of CDK12 deficiency, prior studies have shown that CDK12 controls the expression of many DNA repair genes, including BRCA1 and ATM, by regulating intronic polyadenylation 63–65 .”
BackgroundThe MYCN/Aurora-A complex is a cyclin activating kinase for CDK12Preprint
Müller, M., Eing, L., Uhl, L., Schmitz, M., Kaneva, I. N., Byrne, D. P., Fleischhauer, D., Burgess, S. G., Fischer, S., Gebauer, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.15.633177 · Cited by 4
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications
Singh, N., & Heemers, H. V. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0011 · Cited by 4
Absence of CDK12 in oocyte leads to female infertility
Jansová, D., Sedmikova, V., Berro, F. J., Aleshkina, D., Dvoran, M., Kubelka, M., Rezacova, J., Rutarova, J., Kohoutek, J., & Šušor, A. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07536-w · Cited by 2
“In the oocyte, CDK12/CCNK complexes are abundant in the nucleus, supporting their biological function in transcription [13, 16].”
InfluentialSelf-citationDDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition
Moison, C., Mendoza‐Sanchez, R., Gracias, D., Schuetz, D. A., Spinella, J.-F., Girard, S., Thavonekham, B., Chagraoui, J., Durand, A., Fortier, S., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00448-y · Cited by 3
“…of Ser2 of the C-terminal domain of RNA polymerase II, the CDK12-cyclin K protein complex regulates transcription elongation, focusing on lengthy, exon-rich genes, such as DNA damage response genes (Bartkowiak et al, 2010; Edwards et al, 1998; Kohoutek and Blazek, 2012; Blazek et al, 2011).”
Rajan, N., Khanal, T., Adik, A., Valenciaga, A., Nigam, A., Liyanarachchi, S., & Ringel, M. D. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0124 · Cited by 2
Chen, D., Hu, J., Yu, Y. S., Li, K., Wang, T., Wang, Z., Yuan, Y., Shao, X., Ying, M., Yang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02232 · Cited by 2
CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting
Dudkiewicz-Garbicz, J., & Wlodarski, P. K. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01131-z · Cited by 5
“These kinases ensure expres - sion of long genes critical for homologous recombination, including BRCA1 and ATR [ 2 ].”
Influential
Metadata
- Authors
- Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M.
- Affiliations
- University of California, San Francisco (US)
- MRC Laboratory of Molecular Biology (GB)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-15
- Volume
- 25
- Issue
- 20
- Pages
- 2158-2172
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC3205586
- OpenAlex
- W2123814549
- Cited by
- 522
- References
- 57
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 52 · 2023: 40 · 2022: 35 · 2021: 40 · 2020: 52 · 2019: 45 · 2018: 33 · 2017: 24 · 2016: 29 · 2015: 25 · 2014: 23 · 2013: 24 · 2012: 24
- Type
- posted content
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Development (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (089701)
- Grantová Agentura České Republiky
- National Institutes of Health (GM082250)
- National Institute of General Medical Sciences (P50GM082250, IP50 GM082250)
- National Institute of Allergy and Infectious Diseases (R01AI49104, R01AI049104)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cyclin K, CDK12, CDK13, RNA polymerase II Ser2 phosphorylation, transcriptional regulation, DNA damage response genes, genome stability, BRCA1, ATR, FANCI, FANCD2, spontaneous DNA damage, embryonic lethality
- MeSH terms
- Animals, DNA Damage, HeLa Cells, Humans, Phosphorylation, CDC2 Protein Kinase, Cyclins, Mice, Knockout, Gene Expression Regulation, Developmental, Cyclin-Dependent Kinases, Genomic Instability, Cyclin-Dependent Kinase 9, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.